CME program -
"New Developments in the Treatment of Invasive Fungal Disease"
Highlights from the 12th European Congress of Clinical Microbiology and Infectious Diseases

John G. Bartlett, MD
Department of Medicine
Division of Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, Maryland

• Dr Bartlett reports serving on the HIV advisory board for Abbott Laboratories and Merck & Co, Inc.

John H. Rex, MD, FACP
Department of Medicine
Section of Infectious Diseases
University of Texas Medical School
Houston, Texas

• Dr Rex reports receiving grants and/or research support from, serving as a consultant to, or receiving honoraria from Bristol-Myers Squibb Company; Fujisawa Pharmaceutical Co, Ltd; Gilead Sciences, Inc; Janssen Pharmaceutica; Merck & Co, Inc; Ortho Biotech Products, LP; Pfizer Inc; Schering-Plough Corporation; Lipsome Company, Inc; and Versicor Inc.


Manuel Cuenca-Estrella, MD, PhD
Clinical Researcher
Unidad de Micologia
Instituto de Salud Carlos III
Centro Nacional de Microbiologia
Madrid, Spain

• Dr Cuenca-Estrella reports no financial or advisory relationships with pharmaceutical companies related to this activity.

Renée Grillot, PhD
Parasitologie-Mycologie Médicale
Centre Hospitalier Universitaire et Université Joseph Fourier
Grenoble, France

• Prof Grillot reports no financial or advisory relationships with pharmaceutical companies related to this activity.

Bart-Jan Kullberg, MD
Associate Professor of Medicine
Department of Internal Medicine
University Hospital Nijmegen
Nijmegen, The Netherlands

• Dr Kullberg reports receiving grants and/or research support from Pfizer Inc, and receiving honoraria from Pfizer Inc; Schering-Plough Corporation; and Ortho Biotech Products, LP.

Ruth Matthews, MD, PhD, FRCPath
Research and Development Director
NeuTec Pharma plc
Manchester Royal Infirmary
Manchester, United Kingdom

• Prof Matthews is the Founding Director/Research and Development Director of NeuTec Pharma plc.

John R. Perfect, MD
Professor of Medicine
Associate Professor of Microbiology
Director, Mycology Research Unit
Duke University Medical Center
Durham, North Carolina

• Dr Perfect reports receiving grants and/or research support from Elan Corporation; Fujisawa Pharmaceutical Co, Ltd; Merck & Co, Inc; Pfizer Inc; Pliva dd; and Schering-Plough Corporation.

Advanced Studies in Medicine provides disclosure information from contributing authors, lead presenters, and participating faculty. Advanced Studies in Medicine does not provide disclosure information from authors of abstracts and poster presentations. The reader shall be advised that these contributors may or may not maintain financial relationships with pharmaceutical companies.

Off Label Product Discussion
Faculty have disclosed that their articles have referenced the following off-label/unapproved uses of drugs or products:

Posaconazole — Dr Kullberg
Mycograb® — Prof Matthews

Close this window